AR071885A1 - Proteinas de union al receptor de interleuquina 21 - Google Patents

Proteinas de union al receptor de interleuquina 21

Info

Publication number
AR071885A1
AR071885A1 ARP090101847A ARP090101847A AR071885A1 AR 071885 A1 AR071885 A1 AR 071885A1 AR P090101847 A ARP090101847 A AR P090101847A AR P090101847 A ARP090101847 A AR P090101847A AR 071885 A1 AR071885 A1 AR 071885A1
Authority
AR
Argentina
Prior art keywords
antigen binding
proteins
disorders
interleuquine
union
Prior art date
Application number
ARP090101847A
Other languages
English (en)
Original Assignee
Wyeth Corp
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071885(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Medimmune Ltd filed Critical Wyeth Corp
Publication of AR071885A1 publication Critical patent/AR071885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud proporciona prote¡nas de union y sus fragmentos de union ant¡geno, que se unen espec¡ficamente al receptor humano interleuquina-21 (IL-21R). Las prote¡nas de union pueden actuar como, por ejemplo, antagonistas de la actividad IL-21R, por lo tanto modulando respuestas inmunes en general, y aquellas mediadas por IL-21R en particular. Las composiciones y metodos divulgados se pueden utilizar, por ejemplo, para diagnosticar y/o tratar trastornos asociados con IL-21R, por ejemplo, trastornos inflamatorios, trastornos auto-inmunologicos, alergias, rechazos de transplantes, c ncer, y otros trastornos del sistema inmunologico. Reivindicacion 1: Una prote¡na de union aislada o un fragmento de union ant¡geno de la misma que se une a IL-21R, en donde la prote¡na de union o su fragmento de union ant¡geno comprende al menos una secuencia de amino cidos que es al menos aproximadamente 95% identica con una secuencia de amino cidos seleccionada del grupo que consiste de ID de SEC Nø: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 165-168, 171-193, 213-229, 240, 242, 244, 246 y 248.
ARP090101847A 2008-05-23 2009-05-22 Proteinas de union al receptor de interleuquina 21 AR071885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
AR071885A1 true AR071885A1 (es) 2010-07-21

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101847A AR071885A1 (es) 2008-05-23 2009-05-22 Proteinas de union al receptor de interleuquina 21

Country Status (20)

Country Link
US (2) US8163884B2 (es)
EP (1) EP2297199A1 (es)
JP (1) JP2011523849A (es)
KR (1) KR20110040773A (es)
CN (1) CN102105491A (es)
AR (1) AR071885A1 (es)
AU (1) AU2009248809A1 (es)
CA (1) CA2724915A1 (es)
CL (1) CL2009001284A1 (es)
CO (1) CO6382184A2 (es)
IL (1) IL209328A0 (es)
MX (1) MX2010012811A (es)
MY (1) MY149448A (es)
NZ (1) NZ589330A (es)
PE (1) PE20100141A1 (es)
RU (1) RU2010152690A (es)
SA (1) SA109300315B1 (es)
TW (1) TW201000129A (es)
WO (1) WO2009143523A1 (es)
ZA (1) ZA201008335B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US20130004976A1 (en) * 2009-12-25 2013-01-03 Sekisui Medical Co., Ltd. Human insulin assay and assay reagent
ES2628841T3 (es) * 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
WO2000053761A2 (en) 1999-03-09 2000-09-14 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
EP1353953B1 (en) 2000-05-11 2006-11-29 Genetics Institute, LLC Mu-1, member of the cytokine receptor family
AU2002336676A1 (en) * 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
CA2491320A1 (en) * 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
KR20060015482A (ko) 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
AR051071A1 (es) * 2004-08-05 2006-12-20 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina-21
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
AU2009248809A1 (en) 2009-11-26
PE20100141A1 (es) 2010-02-22
EP2297199A1 (en) 2011-03-23
US20090298167A1 (en) 2009-12-03
MY149448A (en) 2013-08-30
RU2010152690A (ru) 2012-06-27
SA109300315B1 (ar) 2012-08-28
TW201000129A (en) 2010-01-01
CN102105491A (zh) 2011-06-22
ZA201008335B (en) 2014-04-30
CL2009001284A1 (es) 2009-11-27
IL209328A0 (en) 2011-01-31
US20120264919A1 (en) 2012-10-18
MX2010012811A (es) 2011-05-19
JP2011523849A (ja) 2011-08-25
NZ589330A (en) 2012-12-21
KR20110040773A (ko) 2011-04-20
CA2724915A1 (en) 2009-11-26
CO6382184A2 (es) 2012-02-15
WO2009143523A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
AR059604A1 (es) Anticuerpos contra il- 22 humana y usos para los mismos
AR071885A1 (es) Proteinas de union al receptor de interleuquina 21
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
BR112019021991A2 (pt) Proteínas de ligação ao antígeno trem2 e seus usos
PE20150023A1 (es) Proteinas de union a antigeno st2
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
CO6270368A2 (es) Anticuerpos o proteinas funcionales que comprenden una porcion de enlace de antigeno para un objetivo en el polipeptido esclerotina y sus composiciones
BR112015014751A2 (pt) anticorpos anti-tau humanos
CL2011000308A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune.
AR077088A1 (es) Proteinas biespecificas de union a antigeno
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
WO2011063003A3 (en) Peptides and methods for the detection of lyme disease antibodies
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
AR072000A1 (es) Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."

Legal Events

Date Code Title Description
FA Abandonment or withdrawal